Chronic inflammatory demyelinating polyneuropathy and HEV antibody status: A case-control study from Lazio, Italy.

Autor: Moret F; Department of Human Neuroscience, Centre for Rare Neuromuscular Disease, Sapienza University of Rome, Rome, Italy. Electronic address: federica.moret@uniroma1.it., Spada E; Department of Infectious Diseases, Viral Hepatitis and Oncovirus and Retrovirus Diseases, Istituto Superiore di Sanità, Rome, Italy., Ceccanti M; Department of Human Neuroscience, Centre for Rare Neuromuscular Disease, Sapienza University of Rome, Rome, Italy., Libonati L; Department of Human Neuroscience, Centre for Rare Neuromuscular Disease, Sapienza University of Rome, Rome, Italy., D'Andrea E; Department of Human Neuroscience, Centre for Rare Neuromuscular Disease, Sapienza University of Rome, Rome, Italy., Villano U; Department of Infectious Diseases, Viral Hepatitis and Oncovirus and Retrovirus Diseases, Istituto Superiore di Sanità, Rome, Italy., Madonna E; Department of Infectious Diseases, Viral Hepatitis and Oncovirus and Retrovirus Diseases, Istituto Superiore di Sanità, Rome, Italy., Chionne P; Department of Infectious Diseases, Viral Hepatitis and Oncovirus and Retrovirus Diseases, Istituto Superiore di Sanità, Rome, Italy., Carocci A; National Center for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, Rome, Italy., Pisani G; National Center for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, Rome, Italy., Fionda L; Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Rome, Italy., Antonini G; Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Rome, Italy., Petrucci A; Center for Neuromuscular and Neurological Rare Diseases, AO San Camillo Forlanini Hospital, C.ne Gianicolense 87, 00152 Rome, Italy., Bruni R; Department of Infectious Diseases, Viral Hepatitis and Oncovirus and Retrovirus Diseases, Istituto Superiore di Sanità, Rome, Italy., Ciccaglione AR; Department of Infectious Diseases, Viral Hepatitis and Oncovirus and Retrovirus Diseases, Istituto Superiore di Sanità, Rome, Italy., Taliani G; Department of Public Health and Infectious Diseases, Infectious and Tropical Medicine Unit, 'Policlinico Umberto I' Hospital, Sapienza University of Rome, Rome, Italy., Rivano Capparuccia M; Department of Public Health and Infectious Diseases, Infectious and Tropical Medicine Unit, 'Policlinico Umberto I' Hospital, Sapienza University of Rome, Rome, Italy., Nobile-Orazio E; Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy; Department of Medical Biotechnology and Translational Medicine, Milan University, Milano, Italy., Inghilleri M; Department of Human Neuroscience, Centre for Rare Neuromuscular Disease, Sapienza University of Rome, Rome, Italy; IRCCS Neuromed Pozzilli, IS, Italy., Cambieri C; Department of Human Neuroscience, Centre for Rare Neuromuscular Disease, Sapienza University of Rome, Rome, Italy.
Jazyk: angličtina
Zdroj: Journal of the neurological sciences [J Neurol Sci] 2024 Apr 15; Vol. 459, pp. 122959. Date of Electronic Publication: 2024 Mar 12.
DOI: 10.1016/j.jns.2024.122959
Abstrakt: Introduction: Few studies have pointed to the possible role of infectious diseases in triggering Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Given the association of Hepatitis E Virus (HEV) with Guillain Barrè syndrome, we conducted a case-control study to determine the possible association of HEV infection with CIDP, analyzing possible risk factors for acquiring HEV infection in both CIDP patients and controls.
Materials and Methods: 82 CIDP and 260 from the general population have provided some personal information (demographics, anamnestic data and recognized risk factors for HEV infection) and underwent venipuncture blood sampling for virological assays testing for anti-HEV IgG and IgM with ELISA and RNA-HEV performing RT-PCR.
Results: Anti-HEV IgG seropositivity resulted in 32 CIDP patients (39.0%) and in 45 controls (17.3%), indicating a significant association between anti-HEV IgG positivity and CIDP (OR 3.04; 95% CI 1.70-5.43, p-value <0.001), but in multivariate logistic regression the only significant associations with anti-HEV positivity were eating pork liver sausages (OR 10.443, 95% CI 2.268-60.12, p-value 0.004) and IVIg/SCIg administration (OR 31.32, 95% CI 7.914-171.7, p-value <0.001).
Discussion: The higher prevalence of anti-HEV IgG in CIDP patients than in controls could be justified by chronically administering IVIg/SCIg with a passive acquisition of anti-HEV antibodies. Furthermore, all the 20 CIDP patients who underwent IVIg/SCIg administration reported HEV risk factors, so that they could have acquired the infection.
Conclusions: Further studies in a larger CIDP patient sample in treatment with therapy other than IVIg/SCIg are necessary to rule out the possible confounding effect of IVIg/SCIg.
Competing Interests: Declaration of competing interest ENO reports personal fees for Advisory or Scientific Board from ArgenX – Belgium, Danthus - USA, Takeda - Italy and USA, CSL-Behring - Italy and USA, Janssen – USA, Kedrion – Italy, LFB – France, Roche – Switzerland, Sanofi - USA. GA reports conference honoraria, advisory board and travel grants from Kedrion, Alnylam, Alexion, Takeda, Argenx. The other authors report no potential conflicts of interest.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: